trial · primary record
Linvoseltamab
Newly Diagnosed Amyloidosis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 382 |
| Primary completion | 2035-07-25 |
| Primary endpoint | Occurrence of Treatment-Emergent Adverse Events (TEAEs) |
| Registry ID | NCT07901725 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:33.330Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07901725
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.